Search

Sustainable medicines that help minimize environmental impact

How we collaborate with renowned experts to lead the way in reducing solvent waste, as part of our efforts to embed sustainability into our core business.

Leptospirosis dogs pet owner guide

The disease can affect multiple organs in dogs, causing kidney damage, liver failure, and even death. The most effective prevention method is vaccination.

International Women's Day

We celebrate International Women’s Day with this year’s UN Women motto being “Gender Equality Today for a Sustainable Tomorrow”

NEJM-IL-36-Phase-1-GPP-data

Data published in The New England Journal of Medicine show rapid improvement of symptoms in patients with a rare form of pustular psoriasis

CHMP_opinion_Nintedanib_SSc-ILD

Boehringer Ingelheim receives positive CHMP opinion for nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease

EMPRISE-Study

DiaTEC new purification technology Ingelvac CircoFLEX

Boehringer Ingelheim introduces DiaTEC, a new and proprietary purification technology for Ingelvac CircoFLEX®

Groundbeaking of vaccine production center in France

Boehringer Ingelheim breaks ground on its strategic vaccine production center for veterinary public health

Boehringer unveils first global sustainability publication

Boehringer Ingelheim unveils its first global sustainability publication ‘Imagine’

Diabetes

FDA approves Jardiance treatment chronic kidney disease

U.S. FDA approves Jardiance® for treatment of adults with chronic kidney disease

biopharmaceuticals-in-china

Boehringer Ingelheim manufactures the first biopharmaceutical approved in China under new MAH contract manufacturing regulatory system.

Partnering with Constantia Flexibles for augmented reality

Boehringer Ingelheim partnered with Constantia Flexibles to provide an innovative packaging solution which enhances the Nutraxin packaging with augmented reality features.

Results for Jardiance EMPACT-MI phase III trial

Results announced from EMPACT-MI phase III trial investigating the effect of Jardiance® (empagliflozin) on risk of heart failure hospitalization and death in adults following a heart attack

European Metacam® indication expanded to guinea pigs

Boehringer Ingelheim adds a new species to its Metacam® brand in Europe, expanding the indications of this widely-used medicine to guinea pigs.

Cystic Fibrosis Genetherapy Development Option Excercise

Boehringer Ingelheim and Partners Accelerate BI 3720931 Gene Therapy as long-lasting therapeutic option for patients with cystic fibrosis

World Rabies Day 2020 sustainable dog vaccination

Health equity for underserved communities

Introducing initiatives that improve access to healthcare for underserved communities

RE-LY-trial-publication-10-year-anniversary

Boehringer Ingelheim recognises the contribution made in the decade since the RE-LY® trial publication by patients, HCPs and researchers

New indications NexGard, NexGard SPECTRA and Broadline

New therapeutic indications for NexGard®, NexGard SPECTRA® and Broadline® approved by EMA

Arti-cell Forte stem cell-based veterinary product